Ignite Creation Date:
2024-05-06 @ 2:03 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04198571
Status:
COMPLETED
Last Update Posted:
2024-03-26
First Post:
2019-11-05
Brief Title:
Retrospective Chart Review Study to Assess Characteristics Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics Treatment Outcomes and Resource Use Among Adult Patients Hospitalised for Community-Acquired Pneumonia CAP or Complicated Skin and Soft Tissue Infections cSSTI Treated With Zinforo REGISTERED Ceftaroline Fosamil in a Usual Care Setting
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia CAP or Complicated Skin and Soft Tissue Infections cSSTI Treated with Zinforo ceftaroline fosamil in a Usual Care Setting
Detailed Description:
The overall study aim is to provide real world evidence RWE on the characteristics clinical management treatment outcomes and healthcare resource use of adult patients aged 18 years and older admitted to the hospital for CAP or cSSTI who received Zinforo in a usual care setting in Europe and Latin America on or before 31-May-2019
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None